DexCom Inc. (DXCM)
Posted: Mon Dec 14, 2020 10:36 pmnot vested
The company in question is DexCom Inc. (DXCM), and here’s how its GCMs work.
A tiny sensor wire is inserted under the skin of the patient, and wirelessly transmits real-time, dynamic glucose information to a smartphone application or receiver device.
The devices send out the data every 5 minutes, resulting in up to 288 readings in a 24-hour period (a great time saver for healthcare staff).
Under normal circumstances, hospitals wouldn ‘t be ordering these remote monitors because they have yet to be officially approved by the FDA for inpatient use.
However, the FDA realizes that these are trying times. As these devices can help ease some of the pressure healthcare providers are experiencing, the agency is allowing companies to supply them.
That’s a big vote of confidence. But as I mentioned, DexCom is excelling in areas other than just blood-sugar monitoring for COVID patients.
The firm has made a deeper push into software with a new portal that helps users upload and view glucose data. Patients also can save, print, or email the reports, which is an important ability when changing doctors.
Founded in 1999 and based in San Diego, DexCom currently treats patients that are on intensive insulin therapy in 47 countries. In the U.S. and Europe alone that accounts for six million people.
The company is working on new products targeted at treating people with earlier-stage diabetes, a market consisting of 60 million people.
And over the next two years, DexCom plans to deliver $2 billion to $2.5 billion in sales. The firm is aiming for profit margins of 25%, suggesting adjusted earnings of at least $500 million.
Source: Money Morning
The company in question is DexCom Inc. (DXCM), and here’s how its GCMs work.
A tiny sensor wire is inserted under the skin of the patient, and wirelessly transmits real-time, dynamic glucose information to a smartphone application or receiver device.
The devices send out the data every 5 minutes, resulting in up to 288 readings in a 24-hour period (a great time saver for healthcare staff).
Under normal circumstances, hospitals wouldn ‘t be ordering these remote monitors because they have yet to be officially approved by the FDA for inpatient use.
However, the FDA realizes that these are trying times. As these devices can help ease some of the pressure healthcare providers are experiencing, the agency is allowing companies to supply them.
That’s a big vote of confidence. But as I mentioned, DexCom is excelling in areas other than just blood-sugar monitoring for COVID patients.
The firm has made a deeper push into software with a new portal that helps users upload and view glucose data. Patients also can save, print, or email the reports, which is an important ability when changing doctors.
Founded in 1999 and based in San Diego, DexCom currently treats patients that are on intensive insulin therapy in 47 countries. In the U.S. and Europe alone that accounts for six million people.
The company is working on new products targeted at treating people with earlier-stage diabetes, a market consisting of 60 million people.
And over the next two years, DexCom plans to deliver $2 billion to $2.5 billion in sales. The firm is aiming for profit margins of 25%, suggesting adjusted earnings of at least $500 million.
Source: Money Morning